$Mercer International (MERC.US)$ Mercer International Inc. Announces Preliminary Results for the Third Quarter of 2024 and Earnings Conference Call Details Mercer International Inc. (Nasdaq: MERC) reported preliminary financial results for Q3 2024. Key highlights include: - Revenues: $502.1 million - Operating income: $8.8 million - Operating EBITDA: $50.5 million - Net loss: $17.6 million - Liquidity: ~$554 million The company faced unscheduled downtime at its mills, impacting pulp productio...
Mercer's acquisition of MDK is a strategic move to bolster its services for ultrahigh-net-worth clients, a rapidly expanding segment. The deal also aims to broaden Mercer's footprint in the Pacific Northwest market.
The fall in revenue and lack of profitability for Mercer International contribute to a pessimistic market viewpoint. However, the company's substantial dividend payments paint a more comprehensive picture, when considering total shareholder return.
$Mercer International (MERC.US)$The head of India's leading medical research institute said on Wednesday that Mercer's new oral crown drug molnupiravir has "significant safety issues" that may prevent it from joining the country's list of viral treatments. The oral drug, molnupiravir, is said to ultimately stop the replication of the virus by introducing a different mechanism in the genetic material, but it could affect growing human cells.
Mercer International Stock Forum
Mercer International Inc. Announces Preliminary Results for the Third Quarter of 2024 and Earnings Conference Call Details
Mercer International Inc. (Nasdaq: MERC) reported preliminary financial results for Q3 2024. Key highlights include:
- Revenues: $502.1 million
- Operating income: $8.8 million
- Operating EBITDA: $50.5 million
- Net loss: $17.6 million
- Liquidity: ~$554 million
The company faced unscheduled downtime at its mills, impacting pulp productio...
• $A.O. Smith (AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum (CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet (DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals (ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning (GLW.US)$ : CFRA Upgrades to Strong Buy ...
The oral drug, molnupiravir, is said to ultimately stop the replication of the virus by introducing a different mechanism in the genetic material, but it could affect growing human cells.
??
No comment yet